Optimizing Fresh Specimen Staining for Rapid Identification of Tumor Biomarkers During Surgery. by Barth, Connor W et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
10-17-2017 
Optimizing Fresh Specimen Staining for Rapid Identification of 
Tumor Biomarkers During Surgery. 
Connor W. Barth 
Oregon Health and Science University 
Jasmin M. Schaefer 
Oregon Health and Science University 
Vincent M. Rossi 
Dartmouth College 
Scott C. Davis 
Dartmouth College 
Summer L. Gibbs 
Oregon Health and Science University 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medicine and Health Sciences Commons 
Dartmouth Digital Commons Citation 
Barth, Connor W.; Schaefer, Jasmin M.; Rossi, Vincent M.; Davis, Scott C.; and Gibbs, Summer L., 
"Optimizing Fresh Specimen Staining for Rapid Identification of Tumor Biomarkers During Surgery." 
(2017). Open Dartmouth: Published works by Dartmouth faculty. 3974. 
https://digitalcommons.dartmouth.edu/facoa/3974 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 






2017; 7(19): 4722-4734. doi: 10.7150/thno.21527 
Research Paper 
Optimizing fresh specimen staining for rapid identification 
of tumor biomarkers during surgery 
Connor W. Barth1, Jasmin M. Schaefer1, Vincent M. Rossi4, Scott C. Davis4, Summer L. Gibbs1,2,3 
1. Biomedical Engineering Department,  
2. Knight Cancer Institute,  
3. OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR 97201, 
4. Thayer School of Engineering, Dartmouth College, Hanover, NH 03755, 
5. Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756. 
 Corresponding authors: Scott C. Davis, Ph.D., Thayer School or Engineering, Dartmouth College, Hanover, NH 03755; Email: Scott.C.Davis@Dartmouth.edu; Phone: 
603-646-9684 and Summer L. Gibbs, Ph.D., Oregon Health & Science University, Collaborative Life Sciences Building, 2730 SW Moody Ave, Mail Code: CL3SG, Portland, OR 
97201; Email: gibbss@ohsu.edu; Phone: 503-494-8940 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.06.19; Accepted: 2017.09.18; Published: 2017.10.17 
Abstract 
Rationale: Positive margin status due to incomplete removal of tumor tissue during breast conserving surgery 
(BCS) is a prevalent diagnosis usually requiring a second surgical procedure. These follow-up procedures 
increase the risk of morbidity and delay the use of adjuvant therapy; thus, significant efforts are underway to 
develop new intraoperative strategies for margin assessment to eliminate re-excision procedures. One 
strategy under development uses topical application of dual probe staining and a fluorescence imaging strategy 
termed dual probe difference specimen imaging (DDSI). DDSI uses a receptor-targeted fluorescent probe and 
an untargeted, spectrally-distinct fluorescent companion imaging agent topically applied to fresh resected 
specimens, where the fluorescence from each probe is imaged and a normalized difference image is computed 
to identify tumor-target distribution in the specimen margins. While previous reports suggested this 
approach is a promising new tool for surgical guidance, advancing the approach into the clinic requires 
methodical protocol optimization and further validation.  
Methods: In the present study, we used breast cancer xenografts and receiver operator characteristic (ROC) 
curve analysis to evaluate a wide range of staining and imaging parameters, and completed a prospective 
validation study on multiple tumor phenotypes with different target expression. Imaging fluorophore-probe 
pair, concentration, and incubation times were systematically optimized using n=6 tissue specimen replicates 
per staining condition. Resulting tumor vs. normal adipose tissue diagnostic performance were reported and 
staining patterns were validated via receptor specific immunohistochemistry colocalization. Optimal staining 
conditions were tested in receptor positive and receptor negative cohorts to confirm specificity. 
Results: The optimal staining conditions were found to be a one minute stain in a 200 nM probe solution (area 
under the curve (AUC) = 0.97), where the choice of fluorescent label combination did not significantly affect 
the diagnostic performance. Using an optimal threshold value determined from ROC curve analysis on a 
training data set, a prospective study on xenografts resulted in an AUC=0.95 for receptor positive tumors and 
an AUC = 0.50 for receptor negative (control) tumors, confirming the diagnostic performance of this novel 
imaging technique. 
Conclusions: DDSI provides a robust, molecularly specific imaging methodology for identifying tumor tissue 
over benign mammary adipose tissue. Using a dual probe imaging strategy, nonspecific accumulation of 
targeted probe was corrected for and tumor vs. normal tissue diagnostic potential was improved, 
circumventing difficulties with ex vivo tissue specimen staining and allowing for rapid clinical translation of this 
promising technology for tumor margin detection during BCS procedures. 
Key words: breast conserving surgery, fluorescence, image-guided surgery, tumor margin assessment, breast cancer, dual 
probe imaging, dual probe difference specimen imaging 
Introduction 
Breast conserving surgery (BCS), including 
partial mastectomy and lumpectomy, remains the 
most common treatment option for patients with early 









~200,000 breast cancer patients diagnosed annually in 
the United States [1]. However, despite recent 
technological advances and efforts to improve 
surgical methods, 20-60% of these patients are left 
with involved or close surgical margins, determined 
by pathological assessment following completion of 
the surgery [1, 2]. Pathological findings of involved or 
close margins require follow up re-excision surgery 
within days to weeks of the original excision, 
resulting in increased risk of morbidity, undue patient 
stress, increased cost to both the patient and 
healthcare system, as well as delay of adjuvant 
therapy, all negatively affecting patient outcomes 
[2-6]. Technologies currently deployed in the clinic to 
improve margin detection include frozen section 
analysis (FSA) [7], touch prep cytology [8], specimen 
radiography [9], specimen ultrasound [10], and 
radiofrequency spectroscopy [11]. Each technique has 
shown improvement in tumor re-excision rates, but 
sensitivity and specificity performance has been 
mixed and lengthy tissue processing procedures in 
some cases limit translation to the clinic [7, 8, 12-20].  
 It has thus been recognized that rapid, accurate 
approaches that do not compromise tissue integrity 
are needed and widespread efforts are underway to 
develop novel approaches for intra-surgical margin 
assessment. A multitude of optical techniques are 
under development for this application [8, 21-35]. 
These strategies are in various stages of clinical 
translation where the ability to produce high contrast 
and high-resolution images have been demonstrated, 
but requirements of long scan times and in vivo 
application of exogenous contrast agents diminish 
clinical viability. While in vivo administration of 
fluorescent contrast agents is attractive, since it 
enables imaging guidance within the surgical cavity, 
the availability of clinically approved contrast agents 
is limited and securing approval for new agents with 
appropriate safety profiles is a long and challenging 
process [36, 37]. Topical application of tumor-specific 
fluorescent probes is a conceptually simple approach 
to identify tumor in specimen margins and an 
appealing alternative to the difficulties of in vivo 
contrast agent administration. In one iteration of this 
approach, activatable fluorescent probes were used to 
detect the presence of tumor-specific enzyme, 
marking positive tumor margins [38-40]. An 
orthogonal approach uses fluorescently-labeled 
tumor targeting moieties (such as antibodies, 
antibody fragments, peptides, etc.) to rapidly stain, 
wash and image the excised specimen. In principle, 
this technique enables rapid tumor-receptor-specific 
staining of the specimen without compromising 
follow-up pathology and doesn’t require the safety 
profile of agents administered in vivo.  
However, early efforts to deploy this simple 
strategy produced non-specific uptake of targeted 
fluorescent probes in normal tissue despite efforts to 
apply blocking solution prior to staining, particularly 
in surrounding adipose tissue, a main component of 
resected breast specimens. Thus, simple, single-agent 
staining of excised tissue specimens, including tissues 
from BCS resulted in poor diagnostic performance. To 
address this, we and others have shown that 
non-specific uptake can be quantified and removed by 
including a second non-specific companion imaging 
probe in the staining solution and that the targeted 
and untargeted images together improve cancer 
detection [31-35, 41, 42]. In this paradigm, each probe 
is labeled with a spectrally-distinct fluorophore, 
enabling the specific and non-specific probe 
distribution to be assessed with multi-color imaging. 
The targeted and untargeted probe pairs are chosen to 
have similar molecular weights in an attempt to 
ensure similar tissue transport kinetics of both agents. 
Therefore, the normalized difference between the 
targeted and untargeted probes’ fluorescence 
emphasizes the difference between each probe’s 
uptake, enhancing the signal from the tumor 
biomarker-targeted probe. The resulting image is thus 
a direct representation of the targeted probe’s specific 
binding to the tumor biomarker. We have termed this 
approach Dual-Probe Difference Specimen Imaging 
(DDSI). We previously reported a proof-of-concept 
study for the DDSI technique using a HER2-targeted 
probe and a spectrally distinct untargeted probe [41]. 
While the DDSI technique showed a significant 
increase in tumor to surrounding adipose tissue 
contrast and improved diagnostic performance when 
compared to targeted stain alone, the staining 
protocol was not optimized for speed and diagnostic 
accuracy, and many questions remained unanswered. 
To date, a full investigation of the relevant parameter 
space, including stain concentration, incubation times, 
and fluorescent labels has not been reported.  
In this study, we explored this parameter space 
in an effort to optimize the DDSI staining protocol for 
future clinical translation. Throughout this study, we 
used receiver operator characteristic (ROC) curve 
analysis as the metric of evaluation, and acquired 
confirmatory immunohistochemistry (IHC) and 
hematoxylin and eosin (H&E) stained microscopy 
images of tissue samples. In the first set of 
experiments, we examined the effect of stain 
concentration and incubation time on the diagnostic 
performance of HER2-targeted DDSI imaging, with 
the aim of choosing the condition that provided the 
highest diagnostic performance in a short time. Next, 
in an effort to confirm that the reported diagnostic 
performance was not driven or otherwise affected by 





the binding behavior of the fluorescent label itself, an 
underappreciated issue in fluorescence imaging of 
tissue [43], we examined the effect of switching the 
fluorescent labels between targeted and untargeted 
probes. Finally, to evaluate the diagnostic 
performance in a semi-blinded, pre-clinical study, we 
used ROC curve analysis on a training data set to 
define an optimal diagnostic threshold and applied 
this result prospectively to a data set that included 
normal tissue, HER2(+) tumors and HER2(-) tumors. 
Materials & Methods 
General Study Design  
The three primary objectives of this study were:  
1. Identify a tissue staining/washing protocol 
that provided high diagnostic performance within a 
clinically relevant time frame that stained the 
target-of-interest. This was accomplished by repeating 
DDSI imaging for different staining concentrations 
and incubation times (100 and 200 nM, 1 and 10 min), 
where six replicates per condition were completed 
(Fig. 1). 
2. Confirm that the fluorophore label did not 
have a major impact on diagnostic performance. This 
was accomplished by repeating all staining conditions 
(100 and 200 nM, 1 and 10 min, 6 replicates per 
condition), with the fluorescent labels reversed 
between the targeted and untargeted probes (Fig. 1). 
3. Determine the diagnostic accuracy of the 
optimized DDSI method. This was accomplished by 
selecting the optimal staining condition once 
parameter optimization studies were completed with 
6 replicate tumor and adipose tissue pairs per 
condition. A diagnostic threshold derived from ROC 
curve analysis on a training data set was then 
determined and used on a prospective testing data set 
that included normal tissue, HER2(+) and HER2(-) 
tumors. Six replicates per HER2 expression condition 
were used for the testing data set experiments.  
For each replicate, tumor and normal adipose 
tissues were stained with the DDSI protocol resulting 
in a total of 60 tissue pairs. Color and fluorescence 
images were acquired using a custom-built widefield 
imaging system capable of acquiring co-registered 
images of each probe’s fluorescence. Following DDSI 
image processing and analysis, each condition’s 
performance was evaluated using ROC curve analysis 
as assessed through the area under the curve (AUC) 
to determine tumor vs. normal tissue diagnostic 
performance. Confirmatory Her2-IHC and H&E were 
also completed for each sample. 
Fluorophores & Antibodies  
Alexa Fluor 647 (AF647, Thermo Fisher 
Scientific, Waltham, MA) and Cy3B (GE Healthcare 
Life Sciences, Little Chalfont, UK) were used for all 
fluorescence imaging studies. These fluorophores 
were selected because they are photostable, have 
relatively high quantum yields and are readily 
available. Each fluorophore was purchased in its 
N-hydroxysuccinimide (NHS) ester form and 
solubilized in anhydrous DMSO at 10 mM for 
antibody conjugation reactions. Trastuzumab 
(Herceptin, Genentech, South San Francisco, CA, 
molecular weight (MW) = 145.5 kDa) was used as the 
targeted probe for all studies. Lyophilized Herceptin 
was made into a stock solution at 2 mg/mL using 1x 
phosphate buffered saline (1x PBS) at pH 7.4. Donkey 
anti-rabbit IgG (Jackson ImmunoResearch, West 
Grove, PA, MW = 150 kDa) was used as the 
untargeted probe for all studies. 
Mice & Cell Lines  
The MCF7 parent line and MCF7 cell line 
transfected with HER2/neu (MCF7-HER2) [44] were 
grown to 90% confluence and harvested for tumor 
implantation. 32-38 day old female athymic nude 
mice (Homozygous 490, Charles Rivers Labs, 
Wilmington, MA) weighing 19-21 g were used for 
growth of MCF7-HER2 and MCF7 tumor xenografts. 
All animal studies were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Oregon 
Health and Science University (OHSU).  
Tumor Implantation & Growth  
Four days prior to MCF7-HER2 implantation, 
mice were implanted with 0.72 mg/pellet 90 day 
release 17β-estradiol pellets (Innovative Research of 
America, Sarasota, FL), explained as follows. One 
hour prior to pellet implantation, mice were injected 
intraperitoneally (IP) with 0.05 mg/kg buprenorphine 
(Reckitt Benckiser Pharmaceuticals Inc., Slough, UK) 
to mitigate any pain from the procedure. Mice were 
then anaesthetized with 100 mg/kg ketamine 
(Hospira Inc., Lake Forest, IL) and 10 mg/kg xylazine 
(AnaSed, Shenandoah, IA) injected IP. Depth of 
anesthesia was assessed using the toe pinch method to 
ensure mice were fully anesthetized prior to any 
surgical manipulation. In a sterile surgical field, the 
lateral dorsal neck of the mice was sterilized with 
povidine-iodine (Purdue Products, Stamford, CT). A 
small incision (~5 mm) was made on the right side of 
the neck between the right ear and shoulder using 
autoclaved instruments and a single 17β-estradiol 
pellet was placed beneath the skin using a 10-gauge 
trochar (Innovative Research of America, Sarasota, 
FL). The incision was sealed with Vetbond (3M, St. 
Paul, MN) and monitored over the next week for 
healing. Estradiol implantation is necessary for MCF7 
cell line tumorigenicity [44]. 







Fig. 1: Staining protocol and experimental conditions. (A) Schematic of DDSI staining protocol and imaging approach. The parameters for each step of the 
staining protocol are listed in their respective boxes. The dual-stain soak experimental parameters that were optimized are highlighted in red. DDSI image processing 
was performed by subtracting the untargeted image from the targeted image and then dividing by the untargeted image as shown. (B) Table of experimental 
conditions tested to optimize the staining protocol. 
 
Four days later, MCF7-HER2 tumors were 
implanted, detailed as follows. Mice were 
anaesthetized with 100 mg/kg ketamine and 10 
mg/kg xylazine injected IP. The peritoneal region of 
the animal was sterilized with providine-iodine in a 
sterile surgical field. A small incision (~3 mm) was 
made bilaterally adjacent to the inferior nipple on the 
left and right sides of each mouse. Forceps were used 
to retract the mammary adipose pad through the 
incision followed by a 200 µL injection of MCF7-HER2 
cell suspension (1x106 cells) into each mammary 
adipose pad. The injected mammary adipose pad was 
carefully inserted back through the incision after 
which the incision was sealed with Vetbond. All 
incisions were monitored daily for a week to ensure 
healing. Mice were monitored weekly for tumor 
growth and overall health. The tumors were allowed 
to grow for 4-6 weeks or until tumor diameter reached 
1 cm3 as measured by calipers.  
The training data set consisted of a cohort of 15 
mice implanted with MCF7-HER2 tumors bilaterally 
for optimization of the dual probe staining 
concentration and incubation time. Of the 30 total 
implantation sites, 24 tumors grew, which were 
bisected and used in the optimization studies. A 
second cohort of 2 mice were implanted with 
MCF7-HER2 tumors for a testing set for staining with 
the selected optimal probe pair, protein concentration 
and incubation time. Of the 4 total implantation sites, 
3 tumors grew, which were bisected and used in the 
testing set. An additional cohort of 3 mice were 
implanted with the MCF7 parent cell line bilaterally 
for a testing set with HER2 negative tumors. Of the 6 
total implantation sites, 3 tumors grew, which were 
bisected and used in the testing set. 
Antibody-Fluorophore Conjugations  
Each antibody was conjugated to each 
fluorophore, resulting in the following labeled 
antibodies: Herceptin-AF647, Herceptin-Cy3B, 
DkRb-AF647, and DkRb-Cy3B, which were prepared 
individually as follows. The antibody was buffer 
exchanged into 1x PBS, pH 8.0 at a concentration of 
2.0 mg/mL for Herceptin and 1.3 mg/mL for DkRb. 
1.5 µL of the 10 mM fluorophore stock solution in 
anhydrous DMSO was added to 220 µL of Herceptin 
and 1 µL of 10 mM fluorophore stock solution in 
anhydrous DMSO was added to 220 µL of DkRb, 
resulting in a 5:1 fluorophore to antibody molar ratio 
in a total volume of 1 mL. The mixture was shaken 
gently at room temperature for 3 h protected from 
light. The resulting mixture was concentrated in 10 
kDa molecular weight cut off spin filter (MWCO, 
Amicon Ultra 0.5 mL 10 kDa, Fisher Scientific, 
Waltham, MA) into a clean microcentrifuge tube to 
remove unreacted fluorophore, followed by 
purification through a 6 kDa MWCO desalting 
column (Bio-Scale Mini Bio-Gel P-6 5 mL, Bio-Rad, 
Hercules, CA) using a fast protein liquid 
chromatography system (FPLC, NGC Quest 10 Plus, 
Bio-Rad, Hercules, CA). The fluorophore to protein 
ratio for each antibody conjugate was quantified 
using absorbance spectroscopy (SpectraMax M5 
Microplate Reader, Molecular Devices, Sunnyvale, 
CA). The antibody absorbance was measured at 280 
nm (Herceptin extinction coefficient = 225,000 





M-1cm-1, Donkey anti-rabbit extinction coefficient = 
210,000 M-1cm-1). Cy3B absorbance was measured at 
560 nm (Cy3B extinction coefficient = 130,000 
M-1cm-1), while AF647 absorbance was measured at 
650 nm (AF647 extinction coefficient = 270,000 
M-1cm-1). Calibrated absorbance and fluorescence 
spectra and the Beer-Lambert law were used to 
determine the concentration of fluorophore and 
antibody for each conjugate [45]. All 
fluorophore-to-antibody ratios used in this study 
were between 3:1 and 4:1. 
DDSI staining solution was made by mixing 
Herceptin-AF647 with DkRb-Cy3B or Herceptin-Cy3B 
with DkRb-AF647 in a solution containing 1x PBS pH 
7.4, 0.1% Tween-20, and 1% bovine serum albumin 
(BSA). Final antibody solution concentrations and 
probe mixtures used for DDSI staining studies were 
as follows: Herceptin-Cy3B + DkRb-AF647 at 
concentrations of 100 and 200 nM measured by 
protein concentration and Herceptin-AF647 + 
DkRb-Cy3B at concentrations of 100 and 200 nM 
measured by protein concentration. 
Tumor Resection & DDSI Staining 
MCF7-HER2 tumor bearing mice were 
euthanized using CO2 asphyxiation followed by 
cervical dislocation after 4-6 weeks of tumor growth 
or a maximum tumor size of 1 cm3. Tumors were 
extracted and bisected prior to DDSI staining, with 
bisected pairs being used to test different staining 
conditions. Bisection would not be necessary in 
clinical use, but was performed in this study in order 
to test multiple conditions using the same tumor for 
increased control over potential variation in specimen 
composition. For each bisected tumor sample, a 
corresponding mammary adipose sample was 
extracted from each mouse. MCF7-HER2 tumor and 
mammary adipose samples were stained and washed 
together following a previously published procedure 
(Fig. 1A) [41]. Briefly, tumor and adipose sample pairs 
were incubated in 1 mL of 2% BSA in PBS blocking 
solution for 10 min. Then each sample pair was 
incubated in 1 mL of DDSI staining solution for 1 or 10 
min. Specimens were stained with both probes 
simultaneously to minimize the required staining 
time, making the technique feasible for integration 
into routine clinical workflow. Each DDSI stained 
sample pair was transferred to 50 mL of wash solution 
composed of 0.1% Tween-20 in PBS and gently 
agitated for 5 min. Tumor and adipose pairs were 
immediately transferred to glass slides for imaging 
with the bisected cut face facing up towards the light 
source and camera. With two staining solutions at two 
concentrations (100 and 200 nM) and two incubation 
times (1 and 10 min) a total of 48 bisected tumor and 
mammary adipose pairs were collected resulting in 
n=6 tissue pairs per DDSI staining condition for the 
optimization studies (Fig. 1B). Following 
optimization, an additional testing cohort consisting 
of n=6 MCF7-HER2 and n=6 MCF7 tumor specimens 
were stained and imaged for validation of DDSI 
method’s diagnostic ability and subsequent 
immunohistochemical (IHC) analysis, making a total 
of 60 tissue pairs stained and measured for this study. 
DDSI Macroscopic Imaging  
Tumor and adipose tissue pair imaging was 
performed using a custom-built wide field imaging 
system consisting of a QImaging EXi Blue 
monochrome camera (Surrey, British Columbia, CA) 
for fluorescence detection with a removable Bayer 
filter for collecting co-registered color images [46-48]. 
A PhotoFluor II light source (89 North, Burlington, 
VT) was focused onto the field of view (FOV, 34 mm × 
45 mm) through a liquid light guide and used 
unfiltered for white light illumination. For 
fluorescence excitation of the dual probe stain, the 
PhotoFluor II was filtered with a 545 nm ± 12.5 nm or 
620 nm ± 30 nm bandpass excitation filter for Cy3B or 
AF647, respectively. The fluence rate for each channel 
was 12 mW/cm2 and 15 mW/cm2 for the Cy3B and 
AF647 excitation, respectively. Fluorescence was 
collected with a 605 nm ± 35 nm or a 700 nm ± 37.5 nm 
bandpass emission filter for Cy3B or AF647, 
respectively. All filters were obtained from Chroma 
Technology (Bellows Falls, VT). In addition to tumor 
and adipose tissue pairs, an aliquot of each dual probe 
staining solution in a covered optical well plate 
(Greiner Bio-One, Monroe, NC) was imaged for 
normalization between channels and stain 
concentrations. Camera exposure times ranged from 
10-50 ms and 150-500 ms for fluorescence image 
collection of calibration drop images and tissue 
specimens, respectively. Image resolution for 
fluorescence and color images was 70 µm. 
DDSI Image Processing  
Co-registered images captured of targeted and 
untargeted fluorescence were processed and used to 
create DDSI images of each tumor-adipose tissue pair. 
Image processing was completed using 
custom-written MatLab Code (MathWorks, Natick, 
MA). Image processing began by subtracting the 
median background signal from the entire image in a 
user selected region of interest (ROI) in which no 
tissue was present. To account for any fluorescence 
variance between experiments, the staining solutions 
for each study were imaged and a user defined ROI 
was quantified for each probe pair and concentration 
used for staining. Images from each fluorescence 





channel were normalized by dividing each pixel by 
the average intensity value of the ROI representing 
the DDSI staining solution corresponding to the probe 
pair and concentration used for staining. A mask was 
then applied to each normalized image so that only 
pixels of measurable fluorescence (0.8-1.2x the 
average pixel value of the area containing tissue) were 
used in the DDSI image calculation. The DDSI image 
was then calculated as IDDSI = (ITargeted – IUntargeted) / 
IUntargeted. Tumor and normal tissue areas were 
determined via user selected ROIs encompassing the 
entire tissue area and intersected with the tissue mask 
for statistical analysis. 
Confocal Microscopy  
Following macroscopic imaging, representative 
tumor and adipose tissue pairs were imaged 
immediately using the Zeiss LSM880 (Carl Zeiss 
Microscopy GmbH, Jena, Germany) to collect high 
resolution images of the targeted and untargeted 
probe fluorescence. Using a plan-apochromatic 20x 
(NA = 0.8) objective, images were collected with the 
following settings: laser: 561 nm, 10% transmission 
(DPSS 561-10, Cy3B); 633 nm, 2% transmission 
(HeNe633, AF647); beam splitter: MBS 
458/514/561/633; filter: 566-628 nm (Cy3B), 638-755 
nm (AF647); pixel time: 1.5 μs; average: line 1; master 
gain: 750 (Cy3B), 700 (AF647); pinhole size: 90 μm; 
and acquisition area 512 × 512 pixels, 16-bit. Zen 
imaging software (Zeiss) was used to merge each 
fluorescence channel image colorimetrically with the 
red channel representing Cy3B fluorescence and the 
green channel representing AF647 fluorescence. 
IHC Staining & Microscopy  
Following imaging, each tumor and adipose 
tissue pair was flash frozen in optimal cutting 
temperature (OCT) compound for tissue preservation. 
To enable IHC staining of each tissue pair, the OCT 
blocks were thawed and re-embedded in paraffin for 
sectioning, H&E staining, and HER2 IHC staining. 
The tissue face imaged for DDSI analysis was placed 
in the paraffin blocks so that it would be sectioned for 
staining. All blocks were faced prior to collecting 
serial sections for H&E and IHC staining, thus the 
exact tissue face that was imaged for DDSI analysis 
was not used for IHC staining. However, tissue 
within a few hundred microns was used for IHC 
analysis of HER2 expression levels. A different HER2 
antibody (1:400, EP1045Y, ab134182, AbCam, 
Cambridge, MA) targeted to the intracellular domain 
of HER2 was used for IHC, to ensure staining of all 
HER2 proteins, even those already stained with 
Herceptin [49]. After paraffin embedding, H&E, and 
IHC staining was performed by Oregon Health and 
Science University's (OHSU) Histology Shared 
Resources. H&E and IHC slides were imaged using 
the Zeiss AxioScan.Z1 Microscope (Zeiss). Bright field 
images were obtained at 10x magnification. Using the 
ZEN Slide scanner software, the ROI (tumor and 
mammary adipose) was detected using Automatic 
Tissue Recognition due to the visibility of the H&E 
and IHC stains. Six field of views (FOVs) were used to 
set the focus map. The ROI was then scanned at 10x 
magnification, acquiring tiles over the entire tissue 
specimen, which were automatically stitched by the 
ZEN software to create the final image. 
Statistical Analysis  
Statistical analysis was performed using MatLab. 
To determine the tumor-to-normal adipose tissue 
diagnostic detection ability, ROC curves were 
generated for the untargeted probe images, targeted 
probe images, and calculated DDSI images. ROC 
curves and corresponding AUC measurements were 
calculated using the perfcurve function in MatLab on 
a pixel-by-pixel basis with individual pixel values for 
each tissue type used as the response variable input. 
Additionally, the optimal tumor vs. normal adipose 
tissue threshold values were determined using the 
ROC point generated from the perfcurve function and 
back calculated to actual pixel value thresholds. 
Histogram plots of the untargeted probe image, 
targeted probe image and DDSI image pixel values for 
tumor and normal adipose pixels were generated and 
the optimal threshold point determined via ROC 
curve analysis was plotted. Statistical significance 
between staining conditions was determined using 
the method described by Hanley and McNeil [50] 
with standard error measurements and correlation 
coefficients for pixel intensity values in each channel 
used for z-score value calculations. z-score values >2 
were considered statistically significant [50]. 
Sensitivity and specificity measurements were 
determined for the testing dataset using the optimal 
threshold value determined from the optimized DDSI 
staining condition in the training optimization 
studies. 
Results 
DDSI Staining Condition Optimization and 
Qualitative Assessment of HER2 Expression by 
IHC 
 Varied DDSI probe pairs (Herceptin-Cy3B + 
DkRb-AF647, Herceptin-AF647 + DkRb-Cy3B), stain 
solution concentrations (100 and 200 nM), and 
staining incubation times (1 and 10 min) were 
examined to establish a DDSI staining protocol with 
speed and accuracy permitting both diagnostic 





performance and clinical feasibility (Fig. 1B). 
Qualitatively, DDSI images showed improved 
tumor-to-adipose tissue contrast when compared to 
untargeted or targeted probe images across all 
conditions and probe pairs tested (Fig. 2). Upon 
comparison, both probe pairs demonstrated the 
ability to differentiate between tumor and adipose 
tissues, showing that neither fluorophore label was 
dominating the tissue biodistribution kinetics of the 
targeted and untargeted probes [43, 51]. DDSI images 
also showed more homogeneous intensities across 
staining conditions and replicates compared to 
targeted or untargeted single probe images (Fig. 2 & 
S1). IHC assessment of HER2 staining patterns 
revealed similar HER2 expression with DDSI staining 
patterns across probe pairs and staining conditions 
(Fig. 3). By comparison, HER2 IHC staining patterns 
were not well aligned with single probe targeted 
staining patterns, often showing inverse staining 
patterns. Targeted and untargeted probes routinely 
showed similar staining pattern to one another, 
suggesting non-specific uptake dominated the 
staining pattern. DDSI corrected for the non-specific 
uptake, yielding staining patterns that were well 
matched with the ground truth HER2 IHC staining 
patterns (Fig. 3 & S2). 
Diagnostic Potential Quantification and 
Optimal Staining Parameter Selection using 
Training Tumor Xenograft Cohort  
Untargeted, targeted, and DDSI image data was 
quantified using ROC curve analysis to determine the 
optimal probe pair and staining conditions. AUC for 
each ROC curve was calculated to assess the ability to 
differentiate tumor from adipose tissue for each tested 
staining condition (Fig. 4A, 4B, & S3). DDSI 
significantly improved tumor vs. normal adipose 
tissue AUC values when compared to targeted single 
probe staining alone across all DDSI probe pairs and 
tested staining conditions (Fig. 4, Table 1). These 
results are in agreement with a similar and promising 
analysis performed in human breast cancer specimens 
using dual probe ratiometric imaging of SERS 
nanoparticles to guide tumor margin assessment [52]. 
The highest three AUC values were generated using 
the 200 nM, 10 min staining condition for the 
Herceptin-AF647 + DkRb-Cy3B probe pair (AUC = 
0.989), 100 nM, 10 min staining condition for the 
Herceptin-Cy3B + DkRb-AF647 probe pair (AUC = 
0.978), and 200 nM, 1 min staining condition for the 
Herceptin-AF647 + DkRb-Cy3B probe pair (AUC = 
0.974) (Fig. 4A, 4B, & S3). 
 
 
Fig. 2: DDSI staining condition optimization. Representative color, fluorescence, and DDSI images of tumor and adipose tissue pairs following staining using a 
range of dual-stain soak concentrations and incubation times for (A) probe pair A (Herceptin-Cy3b, DkRb-AF647) and (B) probe pair B (Herceptin-AF647, 
DkRb-Cy3b). All images are representative of data collected for n=6 tumor and adipose tissue pairs per staining condition. All untargeted and targeted channel images 
are background corrected, normalized by their exposure time and calibration drop intensity, and displayed on equivalent color scales across staining conditions and 
probe pairs. DDSI images are displayed with equivalent color scales across staining conditions. Scale bars = 5 mm. 






Fig. 3: Immunohistochemical analysis and DDSI staining pattern validation. Representative color, fluorescence, DDSI, H&E, and HER2 targeted IHC 
images of tumor and adipose tissue pairs following staining using a range of dual-stain soak concentrations and incubation times for (A) probe pair A (Herceptin-Cy3b, 
DkRb-AF647) and (B) probe pair B (Herceptin-AF647, DkRb-Cy3b). All images are representative of data collected for n=6 tumor and adipose tissue pairs per 
staining condition. All untargeted and targeted channel images are background corrected, normalized by their exposure time and calibration drop intensity. DDSI 
images are displayed with equivalent color scales across staining conditions. H&E and IHC images were acquired from serial sections of the same tissue face imaged 
in the whole specimen DDSI images. H&E: hematoxylin and eosin; IHC: immunohistochemistry. Scale bars = 5 mm. 
 
Table 1: ROC AUC values and z-statistics for DDSI stain condition optimization.  
 
Probe Pair A 
Targeted: Herceptin-Cy3B, Untargeted: Dk-anti-Rb-AF647 
Probe Pair B 
Targeted: Herceptin-AF647, Untargeted: Dk-anti-Rb-Cy3B 
Stain 
Concentration: 
Incubation Time: Stain 
Concentration: 
Incubation Time: 
1 min 10 min 1 min 10 min 
100 nM 
UT T DDSI UT T DDSI 
100 nM 
UT T DDSI UT T DDSI 
0.532 0.866 0.965 0.586 0.930 0.978 0.705 0.928 0.929 0.612 0.921 0.958 
z-stat: 155.7 z-stat: 114.6 z-stat: 3.1 z-stat: 72.1 
200 nM 
UT T DDSI UT T DDSI 
200 nM 
UT T DDSI UT T DDSI 
0.488 0.880 0.973 0.491 0.844 0.906 0.715 0.962 0.974 0.736 0.977 0.989 
z-stat: 172.2 z-stat: 163.0 z-stat: 29.8 z-stat: 48.2 
*UT: untargeted channel; T: targeted channel; ROC: receiver operator characteristic; AUC: area under curve; z-stat: z-statistic obtained from comparison of targeted vs. DDSI 
ROC AUC values for each staining condition (z-stat > 2 signifies significantly different AUC values). 
 
The 200 nM, 1 min staining condition using the 
Herceptin-AF647 + DkRb-Cy3B probe pair was 
chosen as the optimal staining condition since its AUC 
was not appreciably different than the 10 min staining 
conditions and the 1 min incubation time would be 
more clinically feasible for margin assessment in the 
operating room. Histograms of the untargeted, 
targeted, and DDSI pixel values demonstrated the 
improved separation of intensity distribution between 
MCF7-HER2 tumor and normal adipose tissue using 
the DDSI method compared to the targeted or 
untargeted probe alone (Fig. 4C). Additionally, a 
more normal distribution for both tissue types was 
obtained using DDSI compared to the single probe 
targeted stain, signifying the improvement in ROC 
AUC values (Fig. 4C) and intensity normalization 
between replicates as a result of DDSI (Fig. S1). 
Additionally, the optimal cutoff values determined 
using ROC curve analysis were plotted on the 
untargeted, targeted, and DDSI histograms to 
demonstrate the ability to perform automated 
differentiation between tumor and adipose tissue 
using a single threshold. 
Optimal DDSI Method Validation in 
MCF7-HER2 and MCF7 Testing Tumor 
Xenograft Cohort  
The selected probe pair (Herceptin-AF647 + 





Dk-Rb-Cy3B) and staining condition (200 nM, 1 min) 
was applied to a testing MCF7-HER2 (HER2+) paired 
tumor and normal adipose tissue cohort and to a 
matched MCF7 (HER2-) tumor and normal adipose 
tissue cohort for validation of the diagnostic potential 
of the optimized DDSI staining condition (Fig. 5 & S4). 
MCF7-HER2 tumors stained using the optimal probe 
pair and staining conditions demonstrated similar 
improvements in DDSI tumor vs. normal adipose 
AUC values when compared to the single probe 
targeted stain (Targeted AUC = 0.84, DDSI AUC = 
0.95, z = 131.0). Additionally, similar optimal cutoff 
values to the staining condition optimization training 
MCF7-HER2 tumor cohort were determined for the 
testing cohort upon ROC curve analysis (Fig 5C). 
Applying the optimal threshold value determined 
from the training cohort (Fig. 4C) to the testing cohort 
(Fig. 5C) provided a sensitivity of 91% and a 
specificity of 84% for tumor vs. normal tissue 
differentiation. The MCF7 tumor cohort stained using 
the selected probe pair and staining conditions 
demonstrated significantly lower DDSI image 
intensities and DDSI tumor vs. normal adipose tissue 
AUC values compared to the MCF7-HER2 tumor 
cohort. Additionally, the tumor vs. normal adipose 
tissue AUC value was decreased from 0.67 for the 
single probe targeted stain to 0.50 for DDSI in the 
MCF7 tumor line tumor. This was the expected 
behavior as MCF7 is a HER2 negative cell line that 
should not generate HER2 specific signal; however, 
when targeted probe alone was assessed, some 
nonspecific uptake of HER2 was seen (AUC = 0.67), 
which was corrected using the DDSI protocol (AUC = 
0.50). HER2 targeted IHC completed on the same 
representative tissue confirmed the expected HER2 
overexpression in MCF7-HER2 tumors, which was 
again closely matched with the DDSI pattern. 
Furthermore, high resolution images of the targeted 
probe and IHC staining pattern confirmed the 
membrane bound fluorescence staining pattern 
expected from HER2 targeted imaging (Fig. S5). HER2 
IHC staining showed minimal HER2 expression in 
MCF7 parent line tumors, supporting the DDSI AUC 
of 0.50 between tumor and normal tissues based on 
HER2 expression (Fig. 5). 
Discussion 
 The primary aims of this study were to optimize 
and validate the DDSI staining technique for 
improved tumor margin assessment during BCS. 
Incomplete tumor resection during BCS plagues 
surgical outcomes, requiring expensive, invasive 
follow-up surgery, increasing the chances of 
morbidity, and negatively affecting patient outcomes 
[2-6]. Contrast guided resection techniques have 
shown promise for improved margin assessment 
using molecularly specific probes [53, 54]; however 
clinical translation of contrast agents for in vivo 
applications remains challenging. To circumvent 
these difficulties, staining of the resected tumor 
specimens has gained in popularity. However 
non-specific contrast uptake dominates resected 
specimen staining, significantly decreasing tumor to 
normal tissue contrast. Using our novel DDSI 
technique, non-specific uptake can be overcome and 
excised tumor tissue can be distinguished from 
normal tissue with high sensitivity and specificity 
[41].  
In the present study, we examined a wide range 
of staining conditions where probe concentration, 
staining time and fluorophore were varied from 
conditions used in the prior proof-of-concept study to 
identify a suitable protocol for future clinical studies 
(Fig. 1). We evaluated the diagnostic performance of a 
single condition, which could both minimize staining 
time and optimize diagnostic potential. The 
diagnostic potential was evaluated using a 
semi-blinded, pre-clinical study through ROC curve 
analysis on a training data set to define an optimal 
diagnostic threshold and applied prospectively to a 
testing data set that included normal tissue, HER2(+) 
tumors and HER2(-) tumors. 
The DDSI staining conditions tested provided a 
robust and rapid diagnostic technique for 
intraoperative tumor margin assessment. Across both 
fluorescent probe pairs and all staining conditions, 
DDSI showed improved tumor to normal adipose 
tissue differentiation as compared to targeted probe 
alone (Fig. 2, Fig. 4A & 4B). The fluorophore labels 
chosen for this study, AF647 and Cy3B, did not 
significantly affect DDSI performance, with consistent 
tumor to normal adipose tissue differentiation across 
both fluorophore antibody probe pairs. While probe 
pair B demonstrated an increase in DDSI values 
compared to probe pair A, this increase occurred in 
both tumor and normal tissue equally, causing 
negligible overall change in probe pair B’s diagnostic 
ability over probe pair A (Fig. 2, Fig. 4A & 4B). 
Additionally, the DDSI protocol normalized tumor 
HER2 intensities between staining conditions, where 
intensities were significantly less affected by the 
varied staining parameters than single targeted probe 
intensities (Fig. S1). The selected optimal staining 
condition provided high tumor vs. normal tissue 
sensitivity (97%) and specificity (89%) determined via 
retrospective ROC curve analysis with a 1 min 
incubation in a 200 nM solution of the 
Herceptin-AF647 + DkRb-Cy3B probe pair (Fig. 4C) 
decreasing overall staining time and imaging time to a 
total of 16 min, while improving ability to 





differentiate between benign and malignant tissues. 
Importantly, DDSI staining does not interfere 
with downstream pathology, enabling utilization of 
current gold standard diagnostic methods to validate 
intraoperative observations for first in human clinical 
trials. As a demonstration, DDSI staining patterns 
were correlated to HER2 expression using HER2 
targeted IHC (Fig. 3). DDSI staining patterns were 
found to closely align with HER2 expression levels 
and patterns across staining conditions. By 
comparison, single probe targeted staining patterns 
were not well aligned with IHC staining patterns, 
with higher targeted fluorescence intensities in 
regions of low HER2 IHC expression (Fig. 3). These 
results demonstrate that the DDSI method 
accommodates non-specific uptake of the targeted 
probe as well as other imaging anomalies inherent to 
single probe optical imaging such as variations in 
imaging system illumination power, detector 
non-uniformities, detector working distance, etc. 
Thus, DDSI provided the ability to rapidly visualize 
biomarker-bound fluorescence, enabling specific 




Fig. 4: ROC curve analysis and optimal DDSI staining condition selection. ROC curves and AUC values for untargeted, targeted, and DDSI images of 
tumor vs. normal adipose tissue differentiation following staining using a range of dual-stain soak concentrations and incubation times for (A) probe pair A 
(Herceptin-Cy3b, DkRb-AF647) and (B) probe pair B (Herceptin-AF647, DkRb-Cy3b). (C) Tumor and normal tissue pixel intensity histograms, ROC curves, and 
AUC values for untargeted, targeted, and DDSI images following staining using probe pair B at 200 nM concentration and 1 min incubation time. Optimal points 
determined from ROC curve analysis are displayed on each ROC curve and as a vertical line on each pixel value histogram. ROC: receiver operator characteristic; 
AUC: area under curve; opt pt: optimal point. 






Fig 5: HER2(+) and HER2(-) testing cohort for DDSI staining and IHC validation. (A) Representative color, fluorescence, DDSI, H&E, and HER2 targeted 
IHC images of MCF7-HER2 (HER2+) and MCF7 (HER2-) tumor and adipose tissue pairs following staining using the optimal staining condition (Probe pair B, 200 nM 
concentration, 1 min incubation time). All images are representative of data collected for n=6 tumor and adipose tissue pairs per tumor cell line. All untargeted and 
targeted channel images are background corrected, normalized by their exposure time and calibration drop intensity, and displayed on equivalent color scales. DDSI 
images are displayed with equivalent color scales. H&E and IHC images were acquired from serial sections of the same tissue face imaged in the whole DDSI specimen 
images. Scale bars = 5 mm. (B) Tumor and normal tissue pixel intensity histograms, (C) ROC curves, and AUC values for untargeted, targeted, and DDSI images 
corresponding to each cell line. Optimal points determined from ROC analysis are displayed on each ROC curve (blue marker) and as a vertical line on each pixel 
value histogram. The optimal point determined from the training cohort data is displayed on the MCF7-HER2 tumor specimen ROC curve to demonstrate the 
diagnostic reproducibility under optimal staining conditions (orange marker). H&E: Hematoxylin & Eosin; IHC: immunohistochemistry; ROC: receiver operator 
characteristic; AUC: area under curve; opt pt: optimal point. 
 
 The performance of the selected DDSI protocol 
was confirmed in an independent testing tumor 
cohort consisting of HER2+ (MCF7-HER2) and HER2- 
(MCF7) tumor specimens. The HER2+ testing dataset 
showed similar diagnostic AUC and optimal cutoff 
values to the prior HER2+ training dataset, 
demonstrating the repeatability and robustness of the 
DDSI staining and analysis method. Applying the 
optimal threshold calculated from training dataset 
values, high tumor vs. normal tissue sensitivity (91%) 
and specificity (84%) was achieved. As expected, the 
HER2- testing dataset showed lower DDSI signal 
intensities and AUC values compared to the HER2+ 
tumor line (Fig. 5). Notably, for HER2- tumor 
specimens, both targeted and untargeted AUC values 
were above 0.50, signifying higher uptake in the 
tumor tissue compared to the normal adipose tissue 
even though the tissue lacked the HER2 biomarker. 
DDSI was able to correct for this nonspecific uptake of 
the targeted stain by the HER2- tumor tissue, bringing 
the AUC value back down to the expected value of 
0.50. These results validate the ability to provide 
specific molecular imaging on resected tissues with 
the DDSI technique.  
Continued stain protocol development will be 
necessary to further reduce the overall staining time 
generating a clinically relevant staining protocol. 
Total resected specimen staining time could be 
additionally reduced by optimizing the washing and 
blocking conditions, which can likely be reduced to 
<10 min for rapid margin assessment in the operating 
room. Expanding and screening this technique with a 
panel of tumor specific biomarkers such as epidermal 
growth factor receptor (EGFR), estrogen receptor 
(ER), and progesterone receptor (PgR) for breast 
cancer, is also needed to utilize DDSI tumor margin 
assessment on patient specimens with varied tumor 
subtype, heterogeneous cellular phenotypes and 
expression patterns, where multiplexed biomarker 
imaging could be achieved through the addition of 
other targeted fluorescence channels [55, 56]. This will 
facilitate translation of the DDSI technique to human 
specimens excised during BCS for complete 
validation of this promising technique for margin 
detection during BCS. Although studies testing mixed 
tumor and adipose samples are not feasible using 
xenograft models, DDSI staining on resected human 
breast tissue samples composed of varying 
percentages of tumor and adipose mixed tissues will 
be imperative for validation of the clinical diagnostic 
performance of the DDSI method.  
The animal model system used for this study 
provided a controlled platform that allowed 
examination of several different processing conditions 
and probe pairs; however, as with any translational 
animal study, the model system has its limitations in 
recapitulating the challenges in diagnosing human 
tissue. The small normal tissue volumes and lack of 
infiltrative tumor growth patterns are relevant 
limitations of mouse models for this application. 





However, the dual-probe technique is designed to 
accommodate/remove the effects of diffusion and 
other non-specific kinetic behavior regardless of tissue 
type and structure, and our results suggest that the 
DDSI parameter is indeed reporting receptor-specific 
information. These results also provide a robust, 
evidenced-based protocol for translation to humans. 
The next phase of development involves validating 
the optimal stain protocol identified herein on thick 
slices of discarded human breast specimens from 
tumor mastectomy patients and then initiating an 
observational clinical study in the operating room.  
 In summary, the selected DDSI staining 
technique showed significant improvement in 
distinguishing tumor from normal adipose tissue in 
excised specimens over targeted staining alone. 
Perturbations in antibody-fluorophore probe pairs 
had little effect on DDSI performance with consistent 
tumor vs. normal tissue diagnostic performance 
across all tested staining conditions. Using antibody 
based probes and visible fluorophores, the probe 
penetration and imaging depth are inherently surface 
weighted and likely limited to a few microns at best. 
However, according to new consensus criteria for 
breast cancer margin status, margins are considered to 
be negative for tumor when there is no tumor at the 
“ink” or surface of the resected specimen, making the 
current probe composition viable for clinical 
translation [57]. DDSI was also demonstrated to be an 
accurate reporter of tumor specific molecular 
expression levels of HER2, and provided a validated 
diagnostic method for intraoperative tumor margin 
detection with high sensitivity and specificity for BCS. 
The DDSI framework is generalizable to surgical 
resection of other cancers, and we are actively 
studying its application for other indications. With 
further development and application to a range of 
cancer biomarkers, this technique could provide the 
ability to identify diverse cancer phenotypes for 
improved tumor margin assessment intraoperatively, 
reducing re-excision rates and improving patient 
outcomes. 
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